MAGE-1 Antibody [MZ2E/838] | 33-435

MAGE-1 Antibody [MZ2E/838] | 33-435 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human MAGEA1 protein was used as the immunogen for the MAGE-1 antibody.

Research Area: Cancer

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistology (FFPE) : 0.5-1 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the MAGE-1 antibody should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: MZ2E/838

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Melanoma-associated antigen 1, Antigen MZ2-E, Cancer/testis antigen 11, CT11, MAGE-1 antigen, MAGEA1, MAGE1, MAGE1A

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Recognizes a protein of 42-46kDa, identified as MAGE-1. This mAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL) . The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs) . Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.